Negative in Ames, in vitro chromosome aberration (human lymphocytes) and mouse micronucleus assays
“Opicapone was negative in a standard battery of genetic toxicology (Ames, in vitro chromosomal aberration in peripheral human lymphocytes, in vivo CD-1 mouse micronucleus) assays.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Carcinogenicity
Mouse and rat carcinogenicity studies: no drug-related tumors
“No drug-related tumors were observed in mouse or rat.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Reproductive & developmental
Rat fertility, EFD and PPND: no adverse effects up to 1000 mg/kg/day
“In the reproductive and developmental toxicology studies in rat, opicapone was tested at oral doses up to 1000 mg/kg/day, using standard study designs. No adverse effects on fertility or on embryofetal (EFD) or pre- and postnatal development (PPND) were observed.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Safety pharmacology
No relevant hERG or Purkinje fiber effects; no ECG, respiratory or behavioral effects in rat and monkey
“BIA 9-1067 had no relevant effects on hERG-mediated currents in HEK cells or on action potential of isolated Purkinje fibers. In vivo administration in rat and monkey resulted in no test-article effects on electrocardiograms, respiratory function, or behavior.”
✓ VerifiedFDA pharmacology/toxicology review, p. 88Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative